• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于肝细胞癌预后的基底膜相关长链非编码RNA特征

Basement membrane-related lncRNA signature for the prognosis of hepatocellular carcinoma.

作者信息

Xun Shenmei, Li Xiaocui, Zhuang Qingyuan, Zhu Yefei, Qu Lili

机构信息

The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Department of Gastroenterology, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University,1158 Park Road(E) , Qingpu, Shanghai 201700, China.

出版信息

Heliyon. 2024 May 3;10(10):e30439. doi: 10.1016/j.heliyon.2024.e30439. eCollection 2024 May 30.

DOI:10.1016/j.heliyon.2024.e30439
PMID:38765049
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11096898/
Abstract

Hepatocellular carcinoma (HCC) is the main type of primary liver cancer. This study aimed to develop a basement membrane (BM) related lncRNAs risk signature to evaluate the prognosis of HCC patients. We screened differentially expressed BM-related lncRNAs (DE-BMRlncRNAs) for risk evaluation, and identified six DE-BMRlncRNAs (AC072054.1, NUP50-DT, AC026412.3, AC109322.2, POLH-AS1 and LINC00595) for prognostic risk signature. HCC patients were divided to high or low risk according to median risk score. Our prognostic model predicted that patients with higher risk score had worse prognosis. We also created a nomogram to assist clinical decision-making according to risk score and clinicopathological features. Meanwhile, we confirmed the expression of six lncRNAs in HCC tissue and cells. POLH-AS1 knockdown inhibited the migration and invasion of HCC cells. In conclusion, we established a predictive model based on BMRlncRNAs to predict the prognosis of HCC. Our findings offer a rationale to further explore BM-related biomarkers for HCC.

摘要

肝细胞癌（HCC）是原发性肝癌的主要类型。本研究旨在开发一种与基底膜（BM）相关的长链非编码RNA（lncRNA）风险特征，以评估HCC患者的预后。我们筛选了差异表达的与BM相关的lncRNA（DE-BMRlncRNA）用于风险评估，并鉴定出六个用于预后风险特征的DE-BMRlncRNA（AC072054.1、NUP50-DT、AC026412.3、AC109322.2、POLH-AS1和LINC00595）。根据中位风险评分将HCC患者分为高风险或低风险。我们的预后模型预测，风险评分较高的患者预后较差。我们还根据风险评分和临床病理特征创建了一个列线图，以协助临床决策。同时，我们证实了六种lncRNA在HCC组织和细胞中的表达。POLH-AS1敲低抑制了HCC细胞的迁移和侵袭。总之，我们建立了一个基于BMRlncRNA的预测模型来预测HCC的预后。我们的研究结果为进一步探索HCC与BM相关的生物标志物提供了理论依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/d1a5cb432ec6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/07934888f073/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/4350e67346bb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/17a909c1cdd4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/66ea5c1500a1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/7d969e840b20/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/ba6f2f3eb17a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/aa7a3538095c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/d1a5cb432ec6/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/07934888f073/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/4350e67346bb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/17a909c1cdd4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/66ea5c1500a1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/7d969e840b20/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/ba6f2f3eb17a/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/aa7a3538095c/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c07/11096898/d1a5cb432ec6/gr8.jpg

相似文献

1
Basement membrane-related lncRNA signature for the prognosis of hepatocellular carcinoma.用于肝细胞癌预后的基底膜相关长链非编码RNA特征
Heliyon. 2024 May 3;10(10):e30439. doi: 10.1016/j.heliyon.2024.e30439. eCollection 2024 May 30.
2
A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.铜死亡相关长链非编码 RNA 风险模型预测肝细胞癌患者的预后和免疫治疗疗效。
Biochem Genet. 2024 Jun;62(3):2332-2351. doi: 10.1007/s10528-023-10539-x. Epub 2023 Oct 29.
3
Development and Validation of an Immune-Related lncRNA Signature for Predicting the Prognosis of Hepatocellular Carcinoma.用于预测肝细胞癌预后的免疫相关长链非编码RNA特征的开发与验证
Front Genet. 2020 Sep 4;11:1037. doi: 10.3389/fgene.2020.01037. eCollection 2020.
4
Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.长链非编码 RNA 标志物预测肝细胞癌无复发生存率。
World J Gastroenterol. 2019 Jan 14;25(2):220-232. doi: 10.3748/wjg.v25.i2.220.
5
Assessment of prognostic role of a novel 7-lncRNA signature in HCC patients.评估一种新型7-长链非编码RNA特征在肝癌患者中的预后作用。
Heliyon. 2023 Jul 20;9(8):e18493. doi: 10.1016/j.heliyon.2023.e18493. eCollection 2023 Aug.
6
Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.鉴定五个长链非编码 RNA 标志物以改善肝细胞癌患者的预后预测。
World J Gastroenterol. 2018 Aug 14;24(30):3426-3439. doi: 10.3748/wjg.v24.i30.3426.
7
Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.构建铁死亡相关的九个长链非编码 RNA 标志物用于预测肝细胞癌的预后和免疫反应。
Front Immunol. 2021 Sep 17;12:719175. doi: 10.3389/fimmu.2021.719175. eCollection 2021.
8
Analysis of mA-related lncRNAs for prognostic and immunotherapeutic response in hepatocellular carcinoma.肝细胞癌中与毫安相关的长链非编码RNA用于预后和免疫治疗反应的分析
J Cancer. 2024 Feb 17;15(7):2045-2065. doi: 10.7150/jca.92128. eCollection 2024.
9
An m6A-Related lncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma.一种与m6A相关的长链非编码RNA特征可预测肝细胞癌的预后。
Front Pharmacol. 2022 Mar 30;13:854851. doi: 10.3389/fphar.2022.854851. eCollection 2022.
10
A ferroptosis-associated lncRNAs signature predicts the prognosis of hepatocellular carcinoma.铁死亡相关 lncRNAs 特征可预测肝细胞癌的预后。
Medicine (Baltimore). 2022 Jul 15;101(28):e29546. doi: 10.1097/MD.0000000000029546.

本文引用的文献

1
Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.非小细胞肺癌的肿瘤微环境特征及新型免疫治疗策略
J Natl Cancer Cent. 2022 Oct 20;2(4):243-262. doi: 10.1016/j.jncc.2022.10.002. eCollection 2022 Dec.
2
Trends in high-risk rates and screening rates for the population-based cancer screening program on esophageal, stomach and liver cancer in China, 2010-2016.2010 - 2016年中国基于人群的食管癌、胃癌和肝癌癌症筛查项目的高危率及筛查率趋势
J Natl Cancer Cent. 2021 Jun 9;1(3):101-107. doi: 10.1016/j.jncc.2021.05.001. eCollection 2021 Sep.
3
Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis.
糖元代谢介导的肿瘤微环境中的细胞间通讯影响肝癌预后。
Oncol Res. 2024 Feb 6;32(3):563-576. doi: 10.32604/or.2023.029697. eCollection 2024.
4
Assessment of prognostic role of a novel 7-lncRNA signature in HCC patients.评估一种新型7-长链非编码RNA特征在肝癌患者中的预后作用。
Heliyon. 2023 Jul 20;9(8):e18493. doi: 10.1016/j.heliyon.2023.e18493. eCollection 2023 Aug.
5
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma.构建泛凋亡相关基因模型并分析肝细胞癌肿瘤微环境浸润。
Oncol Res. 2023 Jun 27;31(4):569-590. doi: 10.32604/or.2023.028964. eCollection 2023.
6
Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling.细胞外基质衍生的机械力通过整合素-DDR 信号调控乳腺癌细胞干性和静息状态的转变。
Signal Transduct Target Ther. 2023 Jun 28;8(1):247. doi: 10.1038/s41392-023-01453-0.
7
Tumor microenvironment signaling and therapeutics in cancer progression.肿瘤微环境信号与癌症进展中的治疗策略。
Cancer Commun (Lond). 2023 May;43(5):525-561. doi: 10.1002/cac2.12416. Epub 2023 Apr 2.
8
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.肿瘤进展和免疫逃逸中的细胞外基质重塑：从机制到治疗。
Mol Cancer. 2023 Mar 11;22(1):48. doi: 10.1186/s12943-023-01744-8.
9
Global Epidemiology and Genetics of Hepatocellular Carcinoma.全球肝细胞癌的流行病学和遗传学
Gastroenterology. 2023 Apr;164(5):766-782. doi: 10.1053/j.gastro.2023.01.033. Epub 2023 Feb 2.
10
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.